Filing Flows › Organogenesis Holdings (ORGO) › Q4 2025
Organogenesis Holdings (ORGO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Organogenesis Holdings (ORGO) reported revenue of $226M for the fourth quarter 2025 (Q4 2025), +78% from a year earlier and +50% from the quarter before. Operating margin was 28.1%, net earnings $43.7M (19.4% of revenue).
Organogenesis Holdings, Q4 2025: revenue $226M (+78% year over year), operating margin 28.1%, net earnings $43.7M, operating cash flow $39.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $226M | +50% | +78% |
| Operating profit | $63.3M | +205% | +519% |
| Net earnings | $43.7M | +103% | +470% |
| Operating cash flow | $39.4M | 13× | +260% |
| Free cash flow | $34.8M | 41× | +359% |
What changed
Revenue was $225.6M in Q4 2025, up 78% year over year and up 50% from the previous quarter. Product was the largest line at 100% of revenue.
Operating profit was $63.3M, a 28.1% margin (up 20.0 points year over year). Of the extra revenue versus a year earlier, 54% reached operating profit, above the 8% margin then. The fastest-growing cost line was SG&A (+36%). Net earnings were $43.7M, up 470% year over year. The effective tax rate was 31.1%.
Operating cash flow was $39.4M (up 260% year over year), 90% of net earnings. Non-cash charges added back $4.9M of depreciation and amortization and $4.3M of share-based compensation. Working capital and other items used $13.5M. Capital expenditures of $4.7M left free cash flow of $34.8M.
Questions
What was Organogenesis Holdings' revenue in the fourth quarter 2025?
Organogenesis Holdings (ORGO) reported revenue of $226M for the fourth quarter 2025 (Q4 2025), +78% from a year earlier and +50% from the quarter before.
Was Organogenesis Holdings profitable in the fourth quarter 2025?
Operating profit was $63.3M (28.1% of revenue) and net earnings $43.7M.